Skip to content
MNTS

Momentus Inc.

Momentus Inc. Q4 FY2022 earnings call

March 7, 2023 · fiscal period ended 2022-12

EPS · actual vs est

$-175.07 / $-0.28Miss -62425.0%

Revenue · actual vs est

$120,000 / $500,000Miss -76.0%
Ask about this call

Summary

Generated 2023-03-07

Management highlights

  • Vigoride 3 launched in May 2022, placing 8 satellites into orbit. Vigoride 5 launched in Jan 2023, in good health undergoing commissioning. Vigoride 6 on track for launch in April 2023 after assembly, ground-testing, etc. - Technology development: Testing MET thruster on Vigoride 5, working on Tape Spring Solar Array (TASSA) for Vigoride 6. - New customers: Contracts with CONTEC, CUAVA, FOSSA Systems, and repeat customers. - Government focus: Hired Chris Kinman as CCO to target Defense Department and NASA. - System improvements: Upgraded IT and finance systems, settled class action lawsuit, raised $10M in gross proceeds.
View in transcript ↓

Segment performance

No detailed breakdown of product segments by absolute revenue and revenue contribution % was provided in the transcript as the focus was on Vigoride launches and overall business progress.

View in transcript ↓

Guidance

  • Plan to test MET thruster on Vigoride 5 in coming weeks. - On track to launch Vigoride 6 in April 2023. - Intend to test RPO on Vigoride 7 for reusable vehicle development in Oct 2023. - Focus on growing business with Defense Department and NASA.
View in transcript ↓

Risks

  • Uncertainties in meeting forward-looking statements due to various factors. - Competition in space launch with other companies like SpaceX, relativity, etc. - Impact of regulatory changes on de-orbiting satellites and potential cost implications. - Challenges in rocket development by competitors leading to potential delays or issues.
View in transcript ↓

Q&A highlights

Q: Erik Rasmussen asked about Vigoride 5 milestones and cash burn.

A: John Rood and Dennis Mahoney responded on Vigoride 5 commissioning and monthly cash burn trend.

Q: Josh Corn asked about forward sales pipeline.

A: John Rood discussed growing interest from commercial and government customers, new and repeat customers.

Q: Edison Yu asked about MET testing parameters and Vigoride 7.

A: John Rood explained MET testing plan and confidence in tech upgrades for reusable Vigoride.

Q: James Ratcliffe asked about SpaceX price increases.

A: John Rood talked about existing launch contracts protected from price increase and future impact of new SpaceX pricing.

Q: Michael Mathison asked about backlog and payloads.

A: John Rood provided info on backlog composition and payloads for future launches.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$-175.07$-0.28-62425.0%$-35.01
Revenue$120,000$500,000-76.0%$270,000

Transcript

March 7, 2023

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.